Celgene CFO Jacqualyn Fouse Buys 2,000 Shares
Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases. Celgene Corp. has a market cap of $27.06 billion; its shares were traded at around $58.475 with a P/E ratio of 21 and P/S ratio of 7.5.
Jacqualyn A. Fouse joined CELG as the company’s senior VP and CFO on September 27, 2010. He also served as CFO of Bunge Limited, a global agribusiness company. Prior to his position at Bunge, he was senior VP and CFO at Alcon Labs Inc. since 2006. Fouse is on the board of directors for Dick’s Sporting Goods. He has a B.A. and M.A. in economics from the University of Texas at Arlington.
John Hussman bought 300,000 shares in the quarter that ended on 06/30/2011, which is 0.2918% of the $6.2 billion portfolio of Hussman Economtrics Advisors Inc. Kenneth Fisher owns 280,715 shares as of 06/30/2011, an increase of 22.27% from the previous quarter. This position accounts for 0.0443% of the $38.22 billion portfolio of Fisher Asset Management, LLC. Mario Gabelli owns 8,900 shares as of 03/31/2011, a decrease of 84.74% of from the previous quarter. This position accounts for less than 0.01% of the $13.97 billion portfolio of GAMCO Investors. George Soros sold out his holdings in the quarter that ended on 03/31/2011.
CELG announced non-GAAP net income of $417 million, or non-GAAP diluted earnings per share of $0.89, for the quarter ended June 30, 2011. Non-GAAP net income for the second quarter of 2010 was $323 million, or non-GAAP diluted earnings per share of $0.69. Based on U.S. GAAP, Celgene reported net income attributable to Celgene of $279 million, or GAAP diluted earnings per share of $0.59, for the quarter ended June 30, 2011. GAAP net income for the second quarter of 2010 was $155 million, or GAAP diluted earnings per share of $0.33.
"The quarterly results were outstanding, and reflect the therapeutic value of our novel therapies for patients worldwide," said Bob Hugin, chief executive officer of Celgene Corporation. "We are focused on operational excellence to leverage our global potential and drive both near and long-term industry-leading growth and profitability."
Director Ernest Mario bought 5,000 shares of CELG stock on 08/01/2011 at the average price of $58.1. Ernest Mario owns at least 45,370 shares after this. The price of the stock has increased by 0.65% since. Director Rodman L. Drake bought 500 shares of CELG stock on 08/01/2011 at the average price of $58.54. Rodman L. Drake owns at least 9,260 shares after this. The price of the stock has decreased by 0.11% since. There are mixed trades from other insiders.
CELG has a predictability rating of 1 star.